{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:10:33Z","timestamp":1780409433531,"version":"3.54.1"},"reference-count":39,"publisher":"Shared Science Publishers OG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"Abstract<\/jats:title>\n Cushing syndrome (CS) is caused by an increase in endogenous or exogenous glucocorticoids, leading to major alterations in body composition, including visceral obesity, sarcopenia, osteoporosis, type 2 diabetes, and dyslipidemia. Cardiovascular complications resulting from CS are often lethal. We previously demonstrated that CS induced by oral corticosterone (CORT) supplementation in mice can be prevented by inhibition of the peptide hormone acyl-CoA binding protein (ACBP), encoded by the gene diazepam binding inhibitor (DBI). Here, we investigated whether ACBP\/DBI inhibition could be used to treat, rather than prevent, CS. To this end, we initiated treatment with anti-ACBP\/DBI monoclonal antibodies (mAbs) in mice three weeks after the start of CORT supplementation, when hyperphagia and body weight gain were already established. Two anti-ACBP\/DBI mAbs, 7G4a (specific for mouse ACBP\/DBI only) and 82 (which recognizes both mouse and human ACBP\/DBI), were able to normalize food intake and halt weight gain in mice under continuous CORT treatment. In addition, both mAbs attenuated CORT-induced sarcopenia, adiposity in inguinal, perigonadal, and visceral fat depots, and fully restored metabolic parameters, including type-2 diabetes, insulinemia, free fatty acids, triglycerides, and liver transaminases. In conclusion, neutralization of ACBP\/DBI may serve as an effective therapeutic strategy for the treatment of established CS.<\/jats:p>","DOI":"10.15698\/cst2026.01.314","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T19:51:17Z","timestamp":1769543477000},"page":"1-8","source":"Crossref","is-referenced-by-count":1,"title":["Reversal of Cushing syndrome by antibody-mediated neutralization of ACBP\/DBI"],"prefix":"10.15698","volume":"10","author":[{"given":"Zhe","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolian","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Kepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Kroemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6394","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"issue":"3","key":"b0069e","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-020-0371-y","article-title":"Therapeutic glucocorticoids: Mechanisms of actions in rheumatic diseases","volume":"16","author":"Hardy","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"b00711","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","article-title":"Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment","volume":"16","author":"Chotiyarnwong","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"b00777","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41574-022-00683-6","article-title":"Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions","volume":"18","author":"Li","year":"2022","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"b007dd","article-title":"Holistic burden of illness in patients with endogenous Cushing\u2019s syndrome: A systematic literature review","volume-title":"Endocrinol Diabetes Metab","volume":"7","author":"Page-Wilson","year":"2024"},{"issue":"1","key":"b0088c","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41572-024-00588-w","article-title":"Cushing syndrome","volume":"11","author":"Nieman","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"b00930","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.06.008","article-title":"Endozepines and their receptors: Structure, functions and pathophysiological significance","volume":"208","author":"Tonon","year":"2020","journal-title":"Pharmacol Ther"},{"issue":"9","key":"b00a1d","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13910","article-title":"Acyl coenzyme A binding protein (ACBP): An aging- and disease-relevant \u201cautophagy checkpoint\u201d","volume":"22","author":"Mont\u00e9gut","year":"2023","journal-title":"Aging Cell"},{"issue":"12","key":"b00acc","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/s42255-024-01169-7","article-title":"ACBP orchestrates the metabolic phenotype in Cushing\u2019s syndrome","volume":"6","author":"Paul","year":"2024","journal-title":"Nat Metab"},{"issue":"12","key":"b00b32","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/s42255-024-01170-0","article-title":"Pathogenic role of acyl coenzyme A binding protein (ACBP) in Cushing\u2019s syndrome","volume":"6","author":"Pan","year":"2024","journal-title":"Nat Metab"},{"issue":"3","key":"b00b8c","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1080\/15548627.2024.2437649","article-title":"Autophagy-dependent hepatocyte secretion of DBI\/ACBP induced by glucocorticoids determines the pathogenesis of Cushing syndrome","volume":"21","author":"Pan","year":"2025","journal-title":"Autophagy"},{"issue":"2","key":"b00c26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1530\/JOE-19-0168","article-title":"Chronic hypercortisolism causes more persistent visceral adiposity than HFD-induced obesity","volume":"242","author":"Garc\u00eda-Eguren","year":"2019","journal-title":"J Endocrinol"},{"issue":"4","key":"b00cb3","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.cmet.2019.07.010","article-title":"Acyl-CoA-binding protein is a lipogenic factor that triggers food intake and obesity","volume":"30","author":"Bravo-San\u00a0Pedro","year":"2019","journal-title":"Cell Metab"},{"issue":"8","key":"b00d0d","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/s41418-025-01474-y","article-title":"Neutralization of acyl CoA binding protein (ACBP) for the experimental treatment of osteoarthritis","volume":"32","author":"Nogueira-Recalde","year":"2025","journal-title":"Cell Death Differ"},{"key":"b00e43","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2025.102122","article-title":"Sex-dependent effects of FGF21 on HPA axis regulation and adrenal regeneration after Cushing syndrome in mice","volume":"96","author":"D\u00edaz-Catal\u00e1n","year":"2025","journal-title":"Mol Metabol"},{"issue":"2","key":"b00f09","doi-asserted-by":"crossref","first-page":"E363","DOI":"10.1152\/ajpendo.00487.2002","article-title":"Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression","volume":"285","author":"Ma","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"b00fbd","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1210\/en.2006-0539","article-title":"Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy","volume":"148","author":"Gilson","year":"2007","journal-title":"Endocrinology"},{"issue":"12","key":"b01071","article-title":"The regulation of muscle mass by endogenous glucocorticoids","volume":"6","author":"Braun","year":"2015","journal-title":"Front Physiol"},{"issue":"3","key":"b010cf","doi-asserted-by":"crossref","first-page":"E587","DOI":"10.1152\/ajpendo.00219.2016","article-title":"Cortical bone loss caused by glucocorticoid excess requires RANKL production by osteocytes and is associated with reduced OPG expression in mice","volume":"311","author":"Piemontese","year":"2016","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"b0115c","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1365-2222.2004.01824.x","article-title":"Glucocorticoids up-regulate constitutive interleukin-10 production by human monocytes","volume":"34","author":"Mozo","year":"2004","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"b011cf","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0165-5728(97)00262-2","article-title":"Glucocorticoids increase IL-10 expression in multiple sclerosis patients with acute relapse","volume":"85","author":"Gayo","year":"1998","journal-title":"J Neuroimmunol"},{"key":"b01269","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.111033","article-title":"Exploiting the pro-resolving actions of glucocorticoid-induced proteins Annexin A1 and GILZ in infectious diseases","volume":"133","author":"Vago","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"b012ee","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.2337\/db08-1261","article-title":"Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle","volume":"58","author":"Hong","year":"2009","journal-title":"Diabetes"},{"issue":"3","key":"b01417","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1002\/jcp.29141","article-title":"Loss of interleukin-10 exacerbates early Type-1 diabetes-induced bone loss","volume":"235","author":"Rios-Arce","year":"2020","journal-title":"J Cell Physiol"},{"issue":"12","key":"b014cb","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082608","article-title":"Increased Adiposity in Annexin A1-Deficient Mice","volume":"8","author":"Akasheh","year":"2013","journal-title":"PLOS ONE"},{"issue":"2","key":"b01546","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3390\/ijms23020673","article-title":"Pathophysiology of mild hypercortisolism: From the bench to the bedside","volume":"23","author":"Favero","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"13","key":"b0161e","first-page":"1518","article-title":"An overlooked disease: Minimal autonomous cortisol secretion (MACS). A narrative review","volume-title":"Endocr Metab Immune Disord Drug Targets","volume":"24","author":"Farah","year":"2024"},{"issue":"2","key":"b01691","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3390\/medicina56020069","article-title":"Markers of subclinical cardiovascular disease in patients with adrenal incidentaloma","volume":"56","author":"Szychli\u0144ska","year":"2020","journal-title":"Medicina"},{"key":"b0171b","article-title":"Cortisol excess in chronic kidney disease \u2013 A review of changes and impact on mortality","volume-title":"Front Endocrinol","volume":"13","author":"Sagmeister","year":"2023"},{"issue":"1","key":"b01786","doi-asserted-by":"crossref","first-page":"bvac167","DOI":"10.1210\/jendso\/bvac167","article-title":"Association between aldosterone and hypertension among patients with overt and subclinical hypercortisolism","volume":"7","author":"Inoue","year":"2023","journal-title":"J Endocr Soc"},{"issue":"1","key":"b0181d","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/agm2.12286","article-title":"Unveiling the hidden impact: Subclinical hypercortisolism and its subtle influence on bone health","volume":"7","author":"Lou","year":"2024","journal-title":"Aging Medicine"},{"issue":"7","key":"b018aa","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/s41419-020-2716-5","article-title":"Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)\/diazepam binding inhibitor (DBI)","volume":"11","author":"Joseph","year":"2020","journal-title":"Cell Death Dis"},{"issue":"28","key":"b01901","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2501584122","article-title":"Acyl-CoA-binding protein as a driver of pathological aging","volume":"122","author":"Mont\u00e9gut","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"b01a9a","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12943-024-02098-5","article-title":"Acyl-coenzyme a binding protein (ACBP) - A risk factor for cancer diagnosis and an inhibitor of immunosurveillance","volume":"23","author":"Mont\u00e9gut","year":"2024","journal-title":"Mol Cancer"},{"issue":"3","key":"b01af1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41418-024-01410-6","article-title":"ACBP\/DBI neutralization for the experimental treatment of fatty liver disease","volume":"32","author":"Moti\u00f1o","year":"2025","journal-title":"Cell Death Differ"},{"issue":"7","key":"b01c41","article-title":"Neutralization of acyl coenzyme A binding protein for the experimental prevention and treatment of hepatocellular carcinoma","volume":"6","author":"Li","year":"2025","journal-title":"Cell Rep Med"},{"issue":"41","key":"b01c96","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2207344119","article-title":"ACBP\/DBI protein neutralization confers autophagy-dependent organ protection through inhibition of cell loss, inflammation, and fibrosis","volume":"119","author":"Moti\u00f1o","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"b01dfb","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13751","article-title":"High plasma concentrations of acyl-coenzyme A binding protein (ACBP) predispose to cardiovascular disease: Evidence for a phylogenetically conserved proaging function of ACBP","volume":"22","author":"Mont\u00e9gut","year":"2023","journal-title":"Aging Cell"},{"issue":"1","key":"b01f1f","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2413719","article-title":"Benzodiazepines compromise the outcome of cancer immunotherapy","volume":"13","author":"Mont\u00e9gut","year":"2024","journal-title":"Oncoimmunology"},{"issue":"1","key":"b01fdb","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/s41419-025-08148-0","article-title":"ACBP\/DBI neutralization for the prevention and treatment of malignant and non-malignant liver diseases","volume":"16","author":"Li","year":"2025","journal-title":"Cell Death Dis"}],"container-title":["Cell Stress"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/microbialcell.com\/wordpress\/wp-content\/uploads\/2026a-shen-cell-stress.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T19:51:21Z","timestamp":1769543481000},"score":1,"resource":{"primary":{"URL":"http:\/\/microbialcell.com\/researcharticles\/2026a-shen-cell-stress"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":39,"URL":"https:\/\/doi.org\/10.15698\/cst2026.01.314","relation":{},"ISSN":["2523-0204"],"issn-type":[{"value":"2523-0204","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]}}}